Castle Biosciences Inc. (CSTL) is a renowned commercial-stage dermatological cancer company headquartered in Friendswood, Texas, USA. The company began its operations in 2007 and since then has dedicated its services to developing and commercializing diagnostic and prognostic tests designed to provide physicians and their patients with more accurate and actionable information to guide treatment decisions.
The core philosophy of Castle Biosciences centers around improving health outcomes through more accurate diagnoses. They harness innovations in genomics to create diagnostic tests that, they believe, take the guesswork out of identifying potentially deadly conditions, like uveal (eye) and cutaneous (skin) melanoma, at their earliest and most treatable stages.
Their portfolio of tests prominently features DecisionDx®-Melanoma, a gene expression profile (GEP) test for use in patients diagnosed with melanoma, and DecisionDx®-UM, a GEP test for use in patients diagnosed with uveal melanoma. Both of these tests are designed to predict individual risk of metastasis. Castle Biosciences holds an extensive patent portfolio for its proprietary tests and has been commended for its meticulous research and development process.
Besides cutaneous melanoma and uveal melanoma, the company also offers a prognosis test for cutaneous squamous cell carcinoma, and another that can help to identify the risk of the recurrence of skin cancer. This multifaceted approach towards dermatological cancers showcases the company's commitment to pioneering new ways to combat and manage these diseases.
Despite their focus on dermatological cancers, Castle Biosciences is always on the lookout for opportunities to expand its suite of diagnostic solutions. They are committed to improving the lives of patients across a wide spectrum of cancers and diseases, and it is this patient-centric mindset that informs their continual research and development efforts.
As a publicly-traded company listed on the NASDAQ, Castle Biosciences has become a trusted name in the healthcare industry. The company's steady growth and resilient business model emphasizes their vision to bring the power of genomics to bear on challenging diagnostic problems. It is a leading force in innovative healthcare solutions, enabling patients and physicians to make informed treatment decisions and redefine the trajectory of cancer care outcomes around the world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Castle Biosciences insider Derek Maetzold sold 8,580 shares of the company's stock for approximately $303,131, reducing his direct stake by 28.54%. The transaction was made under a pre-arranged Rule 10b5-1 plan. Despite the insider sale, analysts maintain a "Moderate Buy" rating for Castle Biosciences, with the stock trading near its 52-week high after exceeding revenue and earnings expectations in its latest quarter.
_07_03_2026_03_50_21_133108.jpg)
Castle Biosciences' Chief Commercial Officer, Juvenal Tobin W, sold a total of 6,600 shares in two open-market transactions on September 14 and 15, 2026, at prices ranging from $32.32 to $35.14 per share. Following these sales, Tobin W now holds 58,584 shares, representing approximately 10.1% of his previous holdings. This provides investors with insight into his updated ownership stake in the company.
Castle Biosciences insider Tobin Juvenal sold 3,294 shares of the company's stock for approximately $115,751 on September 15th, reducing his position by 5.32%. Despite this insider sale, the company recently reported strong quarterly revenue and an adjusted loss per share that exceeded analyst expectations. Analysts generally maintain a "Moderate Buy" rating for CSTL with an average price target of $42.
Tobin Juvenal, an insider at Castle Biosciences (NASDAQ:CSTL), sold 3,306 shares of the company's stock on September 14th, 2026, for approximately $106,850. This transaction reduced his total holdings by 5.07% to 61,878 shares. Despite the insider sale, analysts have a "Moderate Buy" consensus rating for CSTL with an average price target of $42.00, following the company's Q2 earnings which surpassed revenue and EPS estimates.
A new decision modeling study by Castle Biosciences (NASDAQ: CSTL) indicates that its TissueCypher test can significantly improve risk-aligned management decisions for patients with Barrett's esophagus. The study found that incorporating TissueCypher results increased appropriate treatment decisions from 59.8% to 75.3%, notably reducing both undertreatment in progressing patients and overtreatment in non-progressing patients. While the study highlights the test's potential clinical utility, it was based on modeling rather than actual patient outcomes, suggesting a need for future real-world studies.
This article analyzes Castle Biosciences Inc. (NASDAQ: CSTL), identifying a near-term weak sentiment within a broader long-term weak bias, despite mid-term strength. It highlights an exceptional risk-reward short setup and outlines three distinct AI-generated trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Short Strategy. The analysis also provides multi-timeframe signal analysis, including support and resistance levels for various time horizons.
Bank of New York Mellon Corp has acquired a new position in Castle Biosciences, Inc. (NASDAQ:CSTL), purchasing 98,018 shares valued at approximately $2.34 million in the second quarter. This investment makes Bank of New York Mellon Corp own about 0.32% of Castle Biosciences. Other institutional investors like Vanguard Group Inc., RTW Investments LP, and Dimensional Fund Advisors LP also adjusted their stakes in the company, while company insiders made significant share sales.
Bank of America Corp DE significantly reduced its stake in Castle Biosciences, selling 195,209 shares and retaining 67,810 shares. Despite this, institutional investors collectively hold 92.6% of the company's stock. Castle Biosciences reported better-than-expected quarterly earnings and revenue, though company insiders have sold a substantial number of shares recently.